Treatment of Bacterial Vaginosis With Dequalinium Chloride Vaginal Tablets and a Test of Cure Using a New Molecular Diagnostic Test for the Diagnosis of Bacterial Vaginosis
| Registry | NCT04057482 |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 58 (Actual) |
| Sponsor | Skaraborg Hospital (Other gov) |
| Conditions | Bacterial Vaginoses |
| Interventions | D (Drug) |
| Dates | start 2015-05-01, primary completion 2017-12-01, completion 2018-04-01, first posted 2019-08-15, last updated 2019-08-15 |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Bacterial Vaginoses All trials of D
. Treatment with dequalinium chloride vaginal tablets for 6 days had a cure rate lower than expected; only 37% of patients were considered cured one month after treatment.
This is the first study to utilize a molecular diagnostic test as a test of cure for bacterial vaginosis. The Nugent score is a reliable method for diagnosing bacterial vaginosis, but similar to traditional clinical diagnostic methods, it is not equally reliable when utilized as a test of cure. This study demonstrated that molecular diagnostic testing can be used as a test of cure and this is the first molecular test that can do that. Treatment with dequalinium chloride vaginal tablets for 6 days had a cure rate lower than expected; only 37% of patients were considered cured one month after treatment.
Sex: Female, ages: 18 Years to 45 Years
Inclusion Criteria: BV Exclusion Criteria: No other infection (Gc, clhlamydia, trihomonas)